Rohan does make those statements, but i think they are more general. PYC targets very very specific genetic diseases (RP11 is about 3% of all RP for example) and PYC has usually got a cure planned, not a treatment. So I dont believe there are actual real competitors out there that are doing exactly what we are doing. They are in the same space, but for different diseases usually. His statements are about other companies doing similar things but for different illnesses, and the comparisons with respect to mcap suggest we are about half price! ( or 1/4 price!)
PYC Price at posting:
12.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)